Comparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndrome

被引：3

作者：

Bouzas, Cristina ^{[1
,2
,3
]}

Pastor, Rosario ^{[2
,4
]}

Garcia, Silvia ^{[1
,2
,3
]}

Monserrat-Mesquida, Margalida ^{[1
,2
,3
]}

Martinez-Gonzalez., Miguel Angel ^{[1
,5
,6
]}

Salas-Salvado, Jordi ^{[1
,7
,8
]}

Corella, Dolores ^{[1
,9
]}

Goday, Albert ^{[1
,10
]}

Martinez, J. Alfredo ^{[1
,11
,12
]}

Alonso-Gomez, Angel M. ^{[1
,13
]}

Fernandez-Barcelo, Olga ^{[14
]}

Vioque, Jesus ^{[15
,16
]}

Romaguera, Dora ^{[1
,3
]}

Lopez-Miranda, Jose ^{[1
,17
]}

Estruch, Ramon ^{[1
,18
]}

Tinahones, Francisco J. ^{[1
,19
]}

Lapetra, Jose ^{[1
,20
]}

Serra-Majema, Lluis ^{[1
,21
]}

Riquelme-Gallegop, Blanca ^{[16
,22
]}

Martin-Sanchez, Vicente ^{[16
,23
]}

Pinto, Xavier ^{[1
,24
]}

Delgado-Rodriguez, Miguel ^{[16
,25
]}

Matia, Pilar ^{[26
]}

Vidal, Josep ^{[27
]}

Cardenas-Salas, Jersy-Jair ^{[28
]}

Daimiel, Lidia ^{[29
]}

Ros, Emilio ^{[1
,30
]}

Toledo, Estefania ^{[1
,5
]}

Manzanares, Josep M. ^{[7
,8
]}

Gonzalez-Monge, Inmaculada ^{[9
]}

Munoz, Miguel-Angel ^{[1
,10
]}

Martinez-Urbistondo, Diego ^{[1
,10
,31
]}

Tojal-Sierra, Lucas ^{[1
,13
]}

Munoz-Bravoaf, Carlos ^{[32
]}

Miralles-Gisbert, Salvador ^{[33
]}

Martin, Marian ^{[3
]}

Garcia-Rios, Antonio ^{[1
,17
]}

Castro-Barquero, Sara ^{[1
,18
]}

Fernandez-Garcia, Jose Carlos ^{[1
,19
]}

Santos-Lozano, Jose Manuel ^{[1
,20
]}

Basterra-Gortari, F. Javier ^{[1
,5
]}

Gutierrez-Carrasquilla, Liliana ^{[7
,8
]}

Guillem-Saiz, Patricia ^{[1
,9
]}

Satorres, Alba ^{[1
,10
]}

Abete, Itziar ^{[1
,12
]}

Sorto-Sanchez, Carolina ^{[1
,13
]}

Diez-Espino, Javier ^{[1
,5
]}

Babio, Nancy ^{[1
,7
]}

Fito, Montse ^{[1
,10
]}

Tur, Josep A. ^{[1
,2
,3
]}

机构：

[1] Inst Salud Carlos III, CIBER Fisiopatol Obesidad & Nutr, Madrid 28029, Spain

[2] Univ Balearic Isl, Res Grp Community Nutr & Oxidat Stress, IUNICS, Palma De Mallorca 07122, Spain

[3] Hlth Res Inst Balearic Isl IdISBa, Palma De Mallorca 07122, Spain

[4] Catholic Univ Avila, Fac Hlth Sci, Avila 05005, Spain

[5] Univ Navarra, Dept Prevent Med & Publ Hlth, IDISNA, Pamplona 31008, Spain

[6] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA USA

[7] Univ Rovira & Virgili, Dept Biochem & Biotechnol, Human Nutr Unit, IISPV,Hosp Univ St Joan, Reus 43201, Spain

[8] Hosp Univ St Joan Reus, Unidad Nutr Lipidos & Endocrinol, IISPV, Reus 43201, Spain

[9] Univ Valencia, Dept Prevent Med, Valencia 46100, Spain

[10] Inst Hosp Mar Invest Med Municipal Invest Med IMI, Unit Cardiovasc Risk & Nutr, Barcelona 08003, Spain

[11] UAM, CSIC, Cardiometabol Precis Nutr Program, IMDEA Food,CEI, Madrid 28049, Spain

[12] Univ Navarra, Dept Nutr Food Sci & Physiol, Ctr Nutr Res, Pamplona 31008, Spain

[13] Univ Basque Country UPV EHU, Osakidetza Basque Hlth Serv, Bioaraba Hlth Res Inst, Araba Univ Hosp, Vitoria 48013, Gasteiz, Spain

[14] Univ Malaga, Dept Nursing, Sch Hlth Sci, Inst Biomed Res Malaga,IBIMA, Malaga 29071, Spain

[15] UMH, ISABIAL, Inst Invest Sanitaria & Biomed Alicante, Alicante 03550, Spain

[16] Inst Salud Carlos III, CIBER Epidemiol & Salud Publ, Madrid 28029, Spain

[17] Univ Cordoba, Reina Sofia Univ Hosp, Lipids & Atherosclerosis Unit, Dept Internal Med,Maimonides Biomed Res Inst Cord, Cordoba 14004, Spain

[18] Univ Barcelona, Hosp Clin, Dept Internal Med, IDIBAPS, Barcelona 08036, Spain

[19] Univ Malaga, Virgen Victoria Hosp, Dept Endocrinol, Malaga 29010, Spain

[20] Distr Sanitario Atenc Primaria Sevilla, Dept Family Med, Seville 41013, Spain

[21] Univ Las Palmas Gran Canaria, Inst Biomed Res, Las Palmas Gran Canaria 35016, Spain

[22] Univ Granada, Dept Prevent Med, Granada 18071, Spain

[23] Univ Leon, Inst Biomed IBIOMED, Leon 24071, Spain

[24] Hosp Univ Bellvitge, Internal Med, Lipids & Vasc Risk Unit, Barcelona 08907, Spain

[25] Univ Jaen, Dept Hlth Sci, Ctr Adv Studies Olive Grove & Olive Oils, Jaen 23071, Spain

[26] Inst Invest Sanitaria San Carlos IdISSC, Dept Endocrinol & Nutr, Madrid 28040, Spain

[27] Univ Barcelona, Hosp Clin, Dept Endocrinol, IDIBAPS, Barcelona 08036, Spain

[28] Fdn Jimenez Diez Univ Hosp, Dept Endocrinol, Madrid 28040, Spain

[29] UAM, CSIC, IMDEA Food, Nutr Control Epigenome Grp,Precis Nutr & Obes Pro, Madrid 28049, Spain

[30] Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Dept Endocrinol & Nutr, Lipid Clin, Barcelona 08036, Spain

[31] HM Sanchinarro, Dept Internal Med, Madrid 28050, Spain

[32] Univ Malaga, Div Prevent Med & Publ Hlth, Inst Biomed Res Malaga, IBIMA, Malaga, Spain

[33] Ctr Salud El Raval, Alicante 03203, Spain

来源：

BIOMEDICINE & PHARMACOTHERAPY | 2023年 / 161卷

基金：

欧洲研究理事会; 欧盟地平线“2020”;

关键词：

Metabolic syndrome; Glucagon-like peptide 1 agonists; GLP-1RA; 4-dipeptidyl peptidase inhibitors; DPP-4I; ANTIDIABETIC DRUG; PHYSICAL-ACTIVITY; IV INHIBITOR; DOUBLE-BLIND; GLP-1; INSULIN; PHARMACOKINETICS; QUESTIONNAIRE; SITAGLIPTIN; MEDICATION;

D O I：

10.1016/j.biopha.2023.114561

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Aims: To assess the comparative effects of glucagon-like peptide-1 receptor agonists (GLP-1RA), 4-dipeptidyl peptidase inhibitors (DPP-4I), and metformin treatment during one year on metabolic syndrome (MetS) com-ponents and severity in MetS patients. Methods: Prospective study (n = 6165 adults) within the frame of PREDIMED-Plus trial. The major end-point was changes on MetS components and severity after one-year treatment of GLP-1RA, DPP-4I, and metformin. Anthropometric measurements (weight, height and waist circumference), body mass index (BM), and blood pressure were registered. Blood samples were collected after overnight fasting. Plasma glucose, glycosylated hemoglobin (HbA1c), plasma triglycerides and cholesterol were measured. Dietary intakes as well as physical activity were assessed through validated questionnaires.Results: MetS parameters improved through time. The treated groups improved glycaemia compared with un-treated (glycaemia Delta untreated:-1.7 mg/dL(+/- 13.5); Delta metformin: -2.5(+/- 23.9) mg/dL; Delta DPP-4I: -4.5(+/- 42.6); mg/dL Delta GLP-1RA: -4.3(+/- 50.9) mg/dL; and HbA1c: Delta untreated: 0.0(+/- 0.3) %; Delta metformin: -0.1(+/- 0.7) %; Delta DPP-4I: -0.1(+/- 1.0) %; Delta GLP-1RA: -0.2(+/- 1.2) %. Participants decreased BMI and waist circumference. GLP-1RA and DPP-4I participants registered the lowest decrease in BMI (Delta untreated:-0.8(+/- 1.6) kg/m2; Delta metformin: -0.8(+/- 1.5) kg/m2; Delta DPP-4I: -0.6(+/- 1.3) kg/m2; Delta GLP-1RA: -0.5(+/- 1.2) kg/m2. and their waist circumference (Delta untreated:-2.8(+/- 5.2) cm; Delta metformin: -2.6(+/- 15.2) cm; Delta DPP-4I: -2.1(+/- 4.8) cm; Delta GLP-1RA: -2.4(+/- 4.1) cm.Conclusion: In patients with MetS and healthy lifestyle intervention, those treated with GLP-1RA and DPP-4I obtained better glycemic profile. Anthropometric improvements were modest.

引用

页数：10

共 50 条

[11] Therapeutic assessment of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase IV inhibitors as potential antidiabetic drugs
Mentlein, R
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2005, 14 (01) : 57 - 64
[12] Effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on colorectal cancer incidence and its precursors
Phyo T. Htoo
John B. Buse
Mugdha Gokhale
M. Alison Marquis
Virginia Pate
Til Stürmer
European Journal of Clinical Pharmacology, 2016, 72 : 1013 - 1023
[13] Effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on colorectal cancer incidence and its precursors
Htoo, Phyo T.
Buse, John B.
Gokhale, Mugdha
Marquis, M. Alison
Pate, Virginia
Sturmer, Til
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 72 (08) : 1013 - 1023
[14] Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 agonists as potential neuroprotective agents
Shaker A.Mousa
Bassam M.Ayoub
NeuralRegenerationResearch, 2019, 14 (05) : 745 - 748
[15] Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 agonists as potential neuroprotective agents
Mousa, Shaker A.
Ayoub, Bassam M.
NEURAL REGENERATION RESEARCH, 2019, 14 (05) : 745 - 748
[16] The Effects of Switching from Dipeptidyl Peptidase-4 Inhibitors to Glucagon-Like Peptide-1 Receptor Agonists on Bone Mineral Density in Diabetic Patients
Huang, Chun-Feng
Mao, Tso-Yen
Hwang, Shinn-Jang
DIABETES METABOLIC SYNDROME AND OBESITY, 2023, 16 : 31 - 36
[17] Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Dipeptidyl Peptidase-4 Inhibitors, and Risk of Hospitalization
Lyu, Beini
Grams, Morgan E.
Chang, Alex
Inker, Lesley A.
Coresh, Josef
Shin, Jung-Im
AMERICAN JOURNAL OF CARDIOLOGY, 2022, 165 : 124 - 130
[18] Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors
Deacon, Carolyn F.
DIABETES OBESITY & METABOLISM, 2007, 9 : 23 - 31
[19] Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists
Dawwas, Ghadeer K.
Smith, Steven M.
Park, Haesuk
CARDIOVASCULAR DIABETOLOGY, 2018, 17
[20] Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists
Ghadeer K. Dawwas
Steven M. Smith
Haesuk Park
Cardiovascular Diabetology, 17

← 1 2 3 4 5 →